SHL Medical expands with new office in Shanghai, China

Zug, Switzerland – June 11, 2025 - This strategic step to expand in Shanghai aligns with the organization’s ambitious global expansion program.The autoinjector market in China is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, advancements in biologics, and a rising preference for self-administered treatments. SHL is on track to overtake the leadership in this market by the end of 2025. The new Shanghai location will serve as a hub for business development, enabling SHL Medical to keep close proximity to existing and new customers.

“SHL already has a 49% market share in the Chinese autoinjector market with nearly 8M autoinjectors sold (source: IQVIA) highlighting our remarkable market penetration and successful strategy. Now, we’re expanding our presence, leveraging our device regulatory expertise, our robust intellectual property, and our extensive track record of successful launches to attract leading innovators", said Markus Puusepp, Chief Growth Officer at SHL Medical.

Located in the prestigious Zhangjiang Hi-Tech Park in Shanghai's Pudong district, SHL Medical's new office is situated in an area renowned for its research in life sciences, software, semiconductors, and information technology.

To discover more about SHL Medical, learn more about our innovative self-injection solutions and engage with our dedicated local team, visit our booth at CPhI China. The event will be held from June 24-26, 2025 at the Shanghai New International Expo Center.